Skip to main content
PMC home page
Springer logoLink to Springer
. 2023 May 17;24(4):673. doi: 10.1007/s40257-023-00784-6

Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Jonathan I Silverberg 1, Charles W Lynde 2,3, Katrina Abuabara 4, Cataldo Patruno 5, Anna de Benedetto 6, Haixin Zhang 7, Ryan B Thomas 7, Gaëlle Bégo-Le-Bagousse 8, Faisal A Khokhar 7, Jignesh Vakil 9, Ainara Rodríguez Marco 10, Noah A Levit 7,✉
PMCID: PMC10293382  PMID: 37193879

Publisher Correction to: American Journal of Clinical Dermatology 10.1007/s40257-022-00754-4

The Original Article was published online on 20 February 2023.

As a result of a publisher error, three percentage symbols were missing in the Graphical Abstract on page 2. The values (with percentage symbols) should read:

IGA 0/1 for dupilumab: 44%.

IGA 0/1 for placebo: 7%.

EASI-75 for placebo: 14%.

The original article has been corrected.

Articles from American Journal of Clinical Dermatology are provided here courtesy of Springer

RESOURCES